What Next for Adamas Pharmaceuticals Inc (ADMS) Stock After Today’s Significant Increase?

September 17, 2017 - By Louis Casey

The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) is a huge mover today! The stock increased 4.82% or $0.99 on September 15, reaching $21.53. About 1.18M shares traded. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has declined 0.40% since September 17, 2016 and is downtrending. It has underperformed by 17.10% the S&P500.
The move comes after 7 months positive chart setup for the $484.73M company. It was reported on Sep, 17 by Barchart.com. We have $22.61 PT which if reached, will make NASDAQ:ADMS worth $24.24M more.

Wall Street await Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to release earnings on November, 2. Analysts forecast EPS of $-1.06, down exactly $0.40 or 60.61 % from 2014’s $-0.66 EPS. After posting $-0.93 EPS for the previous quarter, Adamas Pharmaceuticals Inc’s analysts now forecast 13.98 % negative EPS growth.

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Ratings Coverage

Among 8 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 7 have Buy rating, 1 Sell and 0 Hold. Therefore 88% are positive. Adamas Pharmaceuticals had 20 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Thursday, April 28 by Mizuho. The rating was maintained by JMP Securities on Friday, August 25 with “Market Outperform”. The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) earned “Buy” rating by Piper Jaffray on Thursday, August 31. The stock has “Buy” rating by Zacks on Friday, August 7. The company was initiated on Tuesday, September 22 by Aegis Capital. On Friday, June 17 the stock rating was initiated by Noble Financial with “Buy”. Noble Financial maintained the stock with “Buy” rating in Wednesday, August 9 report. The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has “Buy” rating given on Tuesday, August 15 by Mizuho. As per Wednesday, August 9, the company rating was maintained by Cowen & Co. The company was initiated on Tuesday, January 19 by Cowen & Co.

More notable recent Adamas Pharmaceuticals Inc (NASDAQ:ADMS) news were published by: Fool.com which released: “Why Urban Outfitters, Pure Storage, and Adamas Pharmaceuticals Jumped Today” on August 25, 2017, also Marketwatch.com with their article: “Adamas Pharma shares soar on Parkinson’s dyskinesia drug approval” published on August 24, 2017, Marketwatch.com published: “Adamas Pharma stock surges 7% after negative FDA decision for rival Acorda’s …” on August 29, 2017. More interesting news about Adamas Pharmaceuticals Inc (NASDAQ:ADMS) were released by: Seekingalpha.com and their article: “Adamas Pharmaceuticals: Still Upside After Big Rally” published on August 27, 2017 as well as Marketwatch.com‘s news article titled: “Adamas Pharma says its new Parkinson’s drug isn’t just a more expensive, long …” with publication date: August 29, 2017.

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The company has market cap of $484.73 million. The Firm is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It currently has negative earnings. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.